NCT06522048View on ClinicalTrials.gov

SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Immune Checkpoint Inhibitor-Induced DermatitisStevens-Johnson Syndrome, Drug-InducedToxic Epidermal Necrolysis Due to Drug
Interventions
OTHER

Observational studies do not require intervention

This is an observational retrospective study and does not require any intervention.

Trial Locations (1)

350000

First Affiliated Hospital of Fujian Medical University, Fuzhou

Sponsors

Lead Sponsor

Chao Ji
All Listed Sponsors
lead

Chao Ji

OTHER